verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
Company profile
Ticker
VRNA
Exchange
Website
CEO
David Zaccardelli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Verona Pharma, Inc. ...
VRNA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
20 Mar 24
DEF 14A
Definitive proxy
20 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Strengthens financial flexibility to support the Company’s continued growth
2 Jan 24
8-K
Changes in Registrant's Certifying Accountant
18 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
Transcripts
VRNA
Earnings call transcript
2023 Q4
29 Feb 24
VRNA
Earnings call transcript
2023 Q3
2 Nov 23
VRNA
Earnings call transcript
2023 Q2
3 Aug 23
VRNA
Earnings call transcript
2023 Q1
9 May 23
VRNA
Earnings call transcript
2022 Q4
7 Mar 23
VRNA
Earnings call transcript
2022 Q3
9 Nov 22
VRNA
Earnings call transcript
2022 Q2
9 Aug 22
VRNA
Earnings call transcript
2022 Q1
3 May 22
VRNA
Earnings call transcript
2021 Q4
3 Mar 22
VRNA
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
12 Mar 24
3
Andrew Fisher
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
FMR LLC
9 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
4
DAVID ZACCARDELLI
5 Feb 24
4
Kathleen A. Rickard
5 Feb 24
4
Claire Poll
5 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 257.37 mm | 257.37 mm | 257.37 mm | 257.37 mm | 257.37 mm | 257.37 mm |
Cash burn (monthly) | 4.45 mm | (no burn) | 5.44 mm | 5.29 mm | 4.24 mm | 3.96 mm |
Cash used (since last report) | 26.56 mm | n/a | 32.42 mm | 31.57 mm | 25.30 mm | 23.63 mm |
Cash remaining | 230.81 mm | n/a | 224.94 mm | 225.80 mm | 232.07 mm | 233.73 mm |
Runway (months of cash) | 51.8 | n/a | 41.4 | 42.7 | 54.7 | 59.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 106 |
Opened positions | 21 |
Closed positions | 11 |
Increased positions | 29 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 1.33 tn |
Total shares | 155.95 mm |
Total puts | 78.20 k |
Total calls | 613.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities Fund IV | 46.45 mm | $579.67 mm |
Vivo Ventures VI | 23.49 mm | $157.88 mm |
Vivo Ventures Vii | 23.14 mm | $0.00 |
FMR | 7.11 mm | $150.30 bn |
Ra Capital Management | 6.32 mm | $133.56 bn |
NEA Management | 5.11 mm | $118.06 bn |
Perceptive Advisors | 4.40 mm | $92.96 bn |
Wellington Management | 4.30 mm | $90.97 bn |
Vivo Capital | 4.25 mm | $89.84 bn |
Orbimed Advisors | 3.78 mm | $79.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Feb 24 | Kathleen A. Rickard | Ordinary Shares | Sell | Dispose S | No | Yes | 2.2209 | 36,248 | 80.50 k | 2,731,624 |
1 Feb 24 | Michael Austwick | Share Options Ordinary Shares | Grant | Acquire A | No | No | 2.2938 | 144,000 | 330.31 k | 144,000 |
1 Feb 24 | David Zaccardelli | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.2938 | 480,200 | 1.10 mm | 15,942,592 |
1 Feb 24 | Kathleen A. Rickard | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.2938 | 72,768 | 166.92 k | 2,767,872 |
News
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
4 Mar 24
Wedbush Reiterates Outperform on Verona Pharma, Maintains $33 Price Target
1 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings Preview For Verona Pharma
28 Feb 24
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
22 Jan 24
Press releases
Andrew Fisher Joins Verona Pharma as General Counsel
4 Mar 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
15 Feb 24
Michael Austwick Joins Verona Pharma as Non-Executive Director
1 Feb 24